abil
use
doublestrand
rna
inhibit
gene
express
sequencespecif
rna
interfer
rnai
current
revolution
scienc
medicin
alik
numer
preclin
studi
evalu
rnai
novel
therapeut
modal
battl
gainoffunct
autosom
domin
diseas
cancer
viral
infect
one
emerg
concern
rnai
monotherapi
might
ultim
fail
control
virus
escap
silenc
mutat
andor
rnai
suppress
thu
sophist
strategi
develop
aim
avert
viral
resist
combin
rnai
effector
gene
express
inhibitor
sever
report
alreadi
valid
new
concept
combinatori
rnai
cornai
illustr
versatil
describ
coexpress
rnai
trigger
direct
singl
multipl
viral
cellular
target
studi
document
success
deliveri
trigger
addit
rnaor
proteinbas
silenc
moreov
vector
engin
blend
rnaimedi
gene
inhibit
convent
gene
replac
strategi
collect
effort
open
excit
new
therapeut
avenu
could
also
augment
inher
risk
rnai
technolog
includ
immun
respons
offtarget
oversatur
endogen
pathway
critic
review
cornai
strategi
discuss
requir
transit
clinic
applic
viral
infect
remain
critic
challeng
modern
medicin
continu
pose
complex
global
health
problem
instanc
million
peopl
worldwid
carri
least
one
type
hepat
viru
b
c
mani
develop
clinic
signific
hepat
diseas
chronic
carrier
hepat
b
viru
hbv
high
risk
eventu
die
infectionrel
sequela
endstag
cirrhosi
hepatocellular
carcinoma
even
higher
percentag
patient
chronic
infect
hepat
c
viru
hcv
equal
somber
prognosi
moreov
approxim
million
peopl
worldwid
live
human
immunodefici
viru
hiv
approxim
million
new
infect
million
death
year
case
fatal
rate
almost
hivacquir
immunodefici
syndrom
epidem
impos
one
seriou
burden
human
mortal
global
pandem
caus
newli
emerg
viral
infect
ebola
sever
acut
respiratori
syndrom
coronaviru
avian
influenza
present
threat
human
health
reason
persist
human
virus
emerg
new
infecti
diseas
complex
key
extens
variat
flexibl
viral
genom
result
combin
minim
gener
time
notori
inaccur
reproduct
intrahost
recombin
virus
thu
substanti
genet
advantag
human
host
evolutionari
molecular
arm
race
particularli
appli
rna
virus
hcv
whose
rnadepend
rna
polymeras
incorpor
extrem
number
mutat
per
viral
nucleotid
per
year
eight
per
genom
higher
hbv
dna
viru
even
worrisom
rate
error
three
recombin
event
per
hiv
genom
per
replic
cycl
make
one
fastest
evolv
organ
coupl
logarithm
expans
infect
host
produc
new
particl
day
exert
intens
pressur
natur
immun
system
control
infect
shift
balanc
power
fact
mani
virus
exist
genet
distinct
quasispeci
subtyp
andor
develop
stealth
cun
mechan
outmaneuv
evad
innat
adapt
immun
respons
unfortun
exist
treatment
option
viral
infect
usual
ineffect
limit
instanc
success
rate
hcv
best
even
use
combin
effici
regimen
pegyl
ribavarin
moreov
prevent
recombin
vaccin
viru
hiv
two
vaccin
show
efficaci
recent
phase
iii
clinic
trial
latter
perhap
frustrat
candid
develop
antivir
therapi
singledrug
eg
azidothymidin
strategi
readili
result
evolut
multipli
drugresist
strain
even
combin
drug
highli
activ
antiretrovir
therapi
typic
delay
onset
acquir
immunodefici
syndrom
rid
bodi
one
particularli
promis
power
recent
addit
arsen
antivir
weapon
rna
interfer
rnai
hail
scientif
breakthrough
year
journal
scienc
honor
nobel
prize
physiolog
medicin
andrew
z
fire
craig
c
mello
rnai
natur
phenomemon
gene
silenc
small
duplex
rna
origin
discov
plant
nematod
rnai
known
conserv
evolut
human
although
might
serv
differ
purpos
differ
speci
like
constitut
main
innat
antivir
defens
plant
worm
fli
yet
primari
role
mammal
human
might
process
micro
rna
mirna
small
regulatori
noncod
rna
hundr
mirna
encod
human
genom
mani
transcrib
spatiotempor
manner
follow
express
long
primirna
process
nuclear
enzym
drosha
shorter
premirna
transport
cytoplasm
via
adenosin
triphosphatedepend
rnase
iiilik
dicer
enzym
gener
even
shorter
approxim
nt
doublestrand
rna
small
interf
rna
sirna
role
guid
rnainduc
silenc
complex
homolog
messeng
rna
mrna
induc
either
cleavag
translat
repress
depend
sirnamrna
sequenc
complementar
extrem
effici
specif
process
make
rnai
highli
attract
antivir
therapi
particular
benefit
convent
approach
rnai
innat
cellular
pathway
requir
introduct
trigger
activ
minim
side
effect
importantli
natur
trigger
vari
tailor
viral
target
uniqu
life
cycl
one
option
well
suit
prevent
treat
acut
infect
provid
immedi
effect
topic
applic
sirna
howev
use
might
natur
limit
mucos
tissu
local
access
site
viral
infect
eg
respiratori
femal
genit
tract
eye
notabl
recent
report
sirna
applic
includ
protect
mice
lethal
infect
herp
simplex
treatment
acut
respiratori
syncyti
viru
infect
lead
caus
child
death
latter
applic
current
evalu
phase
clinic
trial
convers
gene
therapi
approach
involv
deliveri
rnai
express
cassett
appropri
treatment
chronic
infect
hbv
hcv
hiv
typic
trigger
mirnalik
sequenc
deriv
natur
mirna
artifici
short
hairpin
rna
shrna
control
rna
polymeras
ii
iii
promot
cassett
small
thu
readili
incorpor
establish
gene
therapi
vector
lentivirus
aav
adenoassoci
virus
instanc
recent
use
latter
aav
serotyp
express
antihbv
shrna
liver
hbvtransgen
mice
result
effici
persist
viral
suppress
anoth
gener
advantag
rnai
antivir
therapi
trigger
perfect
viral
sequenc
complementar
induc
target
cleavag
particular
positivestrand
rna
virus
eg
hiv
hcv
sever
acut
respiratori
syndrom
coronaviru
offer
possibl
suppress
pathogen
actual
erad
host
last
least
rnai
silenc
requir
minim
target
nt
might
suffici
cosuppress
relat
viral
isol
studi
lee
et
al
point
larg
grow
bodi
work
suggest
rnai
suppress
virtual
everi
class
viru
whether
base
dna
rna
whether
carri
doubleor
singlestrand
genom
unfortun
grow
number
studi
concurr
suggest
rnai
might
face
obstacl
hamper
monotherapi
past
particular
viral
escap
paradox
regard
sequenc
specif
rnai
turn
disadvantag
singl
nucleotid
chang
target
abolish
mrna
degrad
provid
viral
mutant
growth
advantag
rnai
pressur
alreadi
illustr
varieti
report
among
first
gitlin
et
al
note
prolong
incub
poliovirusinfect
sirnatr
cell
result
enrich
rnairesist
point
mutant
ident
find
document
hcv
randal
et
al
report
loss
sirna
activ
genotyp
mutant
viru
differ
nt
wilson
richardson
valid
fact
subtl
chang
inde
suffici
permit
viral
escap
show
success
monosirna
treatment
hcv
replicon
cell
line
led
multipl
point
mutat
hcv
genom
loss
sirna
function
phenomenon
found
consist
hiv
first
report
boden
et
al
isol
point
mutant
constant
growth
antitat
shrnaexpress
cell
hiv
propens
escap
confirm
da
et
al
lee
et
al
identifi
emerg
nef
gag
mutant
rnai
pressur
interestingli
westerhout
et
al
realiz
hiv
sporad
escap
mutat
alter
local
genom
secondari
structur
oppos
singl
nucleotid
chang
regardless
mechan
high
propens
rapid
escap
mutat
combin
high
natur
genet
divers
make
find
singl
conserv
effici
viral
target
sequenc
almost
imposs
second
problem
rnai
monotherapi
interact
human
virus
host
might
far
complex
origin
thought
contrari
initi
belief
rnai
part
human
innat
antivir
immun
respons
grow
evid
suggest
exist
viral
encod
suppressor
rnai
silenc
srss
surpris
doublestrand
rna
often
gener
viral
replic
expos
viru
host
rnai
like
exert
pressur
evolv
antirnai
countermechan
fascin
howev
learn
mani
differ
approach
human
virus
might
taken
develop
srss
frequent
among
plant
insect
virus
first
mammalian
exampl
influenza
vaccinia
protein
might
counteract
rnai
pathway
via
nonspecif
sequest
doublestrand
rna
thu
compet
dicer
substrat
howev
main
function
inhibit
protein
kinas
r
rnai
suppress
shown
nonvertebr
cell
thu
far
adenovirusencod
virusassoci
rna
short
mirnalik
molecul
accumul
copi
number
per
infect
cell
anoth
exampl
recent
studi
suggest
virusassoci
rna
outcompet
transloc
endogen
mirna
addit
competit
suppress
dicer
activ
similarli
propos
hcv
core
hiv
tat
protein
inhibit
rnai
via
dicer
bind
hiv
might
also
attenu
rnai
via
second
mechanismsequest
transactiv
respons
rnabind
protein
essenti
rnainduc
silenc
complex
compon
transactiv
respons
region
element
hand
strike
note
human
virus
hijack
rnai
machineri
carri
replic
strategi
might
seem
counterintuit
one
remark
exampl
hcv
subvert
liverspecif
mirna
gene
express
moreov
virus
recent
found
encod
mirna
albeit
case
eg
hiv
epsteinbarr
viru
without
evid
function
genet
signific
except
mirna
whose
function
appear
inhibit
antigen
late
infect
reduc
suscept
viru
activ
cytotox
lymphocyt
knowledg
interact
virus
rnai
pathway
expand
continu
shape
therapeut
strategi
viral
exploit
cellular
factor
offer
novel
mean
clinic
interfer
eg
sequestr
endogen
viral
encod
mirna
moreov
put
presenc
viral
srss
rais
need
target
suppressor
directli
block
earli
stage
viral
life
cycl
prevent
accumul
combin
need
compens
natur
divers
rapid
evolut
make
develop
effici
antivir
therapi
challeng
goal
emerg
solut
thwart
viral
evolut
circumv
relat
issu
multiplex
rnai
trigger
combin
silenc
gene
express
novel
approach
compar
hiv
highli
activ
antiretrovir
therapi
best
describ
combinatori
rnai
cornai
hold
signific
promis
convent
monotherapi
first
foremost
applic
silenc
cocktail
multipl
conserv
viral
sequenc
increas
chanc
avert
escap
mutant
consid
evolutionari
leap
viru
would
make
stochast
comput
model
predict
strong
express
four
individu
antihiv
shrna
might
alreadi
suffic
prevent
viral
escap
second
cornai
therapi
blend
inhibitor
viral
cellular
gene
express
maxim
efficaci
minim
risk
mutat
escap
particularli
promis
target
viral
cell
surfac
receptor
whose
silenc
would
block
earliest
step
viral
infect
also
strand
viru
outsid
cell
thu
prolong
time
avail
detect
immun
system
third
combin
rnai
trigger
ribozym
inhibitor
gene
express
allow
concurr
block
viral
encod
srss
direct
target
viral
genom
andor
cellular
factor
mix
rnai
unrel
silenc
also
minim
potenti
risk
associ
highlevel
mishrna
express
cell
figur
comprehens
summar
variou
recent
report
cornai
strategi
focu
vectormedi
gene
therapi
approach
believ
main
cornai
applic
longterm
suppress
persist
human
virus
hcv
hiv
also
includ
exampl
function
genom
treatment
nonvir
disord
howev
note
initi
proofsofprincipl
cornai
obtain
use
sirna
exampl
includ
studi
kronk
et
al
use
librari
endoribonucleaseprepar
sirna
block
hcv
replicon
cell
cultur
although
approach
seem
use
way
inhibit
multipl
viral
genotyp
avert
escap
clinic
applic
remain
unclear
similarli
wilson
richardson
coelectropor
two
distinct
sirna
replicon
cell
suppress
resist
hcv
mutant
group
use
sirna
cocktail
enhanc
inhibit
hiv
sever
acut
respiratori
syndrom
coronaviru
footandmouth
diseas
viru
concatemer
singl
rnai
trigger
figur
repres
simplest
exampl
cornai
report
sporad
date
intend
rais
intracellular
shmirna
level
might
especi
use
viral
target
replic
spread
high
enough
rate
outcompet
lowlevel
rnai
might
also
benefici
limit
site
within
singl
target
simultan
inhibit
multipl
target
eg
viral
genotyp
via
conserv
site
likewis
could
balanc
low
vector
effici
promot
strength
would
otherwis
prevent
adequ
shmirna
express
howev
better
way
increas
intracellular
shmirna
level
might
use
inher
stronger
rnai
promot
nevertheless
discuss
strategi
essenti
prove
feasibl
concaten
hairpin
rna
illustr
key
issu
gonzalez
et
al
use
individu
promot
express
six
copi
shrna
target
site
conserv
classic
hla
class
gene
hla
b
c
construct
efficaci
valid
transient
transfect
tcell
line
subsequ
measur
surfac
hla
abc
antigen
predict
rais
shrna
copi
number
result
progress
rnai
improv
correl
increas
detect
shrna
express
effect
stabli
maintain
month
absenc
interferon
ifn
product
mediat
expect
protect
cytotox
tlymphocyt
respons
gonzalez
et
al
also
abl
introduc
six
shrna
copi
primari
cell
knock
hla
although
result
compar
result
lower
shrna
number
interestingli
increas
shrna
copi
augment
transient
rnai
effect
longer
stabl
reason
studi
like
includ
toxic
genet
instabl
zhou
et
al
among
first
demonstr
possibl
multiplex
artifici
mirna
use
modifi
hairpin
target
human
superoxid
dismutas
fuse
luciferas
report
express
two
copi
separ
nt
singl
cytomegaloviru
promot
transient
cotransfect
cell
compar
singl
hairpin
tandem
vector
surprisingli
fail
yield
higher
sirna
level
better
target
knockdown
instead
author
note
decreas
rnai
tandem
plasmid
reason
unclear
studi
thu
strongli
suggest
need
better
understand
rule
mirna
concatemer
similarli
curiou
result
report
group
transgen
mice
plasmid
express
ubiquitin
c
promot
inject
fertil
egg
yield
two
line
carri
singl
three
mirna
copi
singlecopi
line
higher
sirna
level
correl
better
sod
knockdown
cross
line
yield
bigen
heterozyg
mice
express
even
higher
sirna
level
show
near
sod
knockout
phenotyp
studi
first
describ
hairpin
rna
multimer
transgen
mice
puzzl
lack
correl
mirna
copi
number
rnai
efficaci
remain
studi
sun
et
al
concaten
antisphas
kinaseassoci
protein
antiandrogen
receptor
hairpin
cytomegaloviru
promot
line
result
gonzalez
et
al
increas
mirna
number
one
two
result
enhanc
sirna
level
rnai
follow
lentivir
deliveri
cell
howev
addit
third
copi
yield
margin
disproport
smaller
increas
perplexingli
efficaci
singl
hairpin
could
also
increas
ad
irrelev
second
mirna
vector
suggest
link
mirna
process
efficaci
rather
direct
effect
copi
number
interest
possibl
remain
investig
recent
chung
et
al
test
construct
base
distinct
mirna
came
differ
conclus
concatemer
eight
antiluciferas
mirna
singl
ubiquitin
c
promot
result
progress
increas
rnai
reason
obviou
discrep
earlier
attempt
unclear
could
relat
use
two
differ
mir
versu
may
affect
hairpin
fold
stabil
moreov
studi
also
differ
posit
mirna
exon
intron
well
natur
length
flank
sequenc
known
crucial
mirna
process
anoth
remark
find
work
construct
efficaci
increas
inclus
second
intron
upon
remov
polyadenyl
site
although
confirm
experiment
interest
specul
modif
increas
nuclear
retent
primari
transcript
therebi
facilit
mirna
process
togeth
studi
alreadi
clearli
highlight
feasibl
express
multipl
shmirna
singl
construct
although
exist
therapeut
applic
point
vector
employ
mirna
appear
prefer
express
multipl
hairpin
allow
use
singl
promot
offer
potenti
spatiotempor
cornai
control
howev
strike
discrep
among
studi
exemplifi
need
deeper
investig
rule
govern
effici
mirna
process
certainli
factor
hairpin
number
numer
paper
recent
provid
proofsofconcept
approach
coexpress
multipl
shmirna
singl
vector
use
nonvir
viral
target
hcv
hiv
exampl
figur
c
brief
two
differ
goal
establish
cornai
surrog
genet
tool
basic
studi
allow
dissect
overlap
function
individu
factor
biochem
pathway
ii
relev
context
review
elucid
use
cornai
treatment
prevent
viral
infect
escap
cotarget
multipl
viral
andor
cellular
gene
yu
et
al
among
first
appli
cornai
approach
studi
gene
function
via
simultan
inhibit
multipl
endogen
mrna
design
two
shrna
separ
promot
target
glycogen
synthas
kinas
two
relat
enzym
involv
variou
cellular
process
human
disord
stabli
cotransfect
cell
cornai
isoform
led
addit
increas
express
glycogen
synthas
kinas
target
compar
inhibit
individu
enzym
report
thu
exemplifi
use
cornai
function
analys
moreov
impli
possibl
treatment
diseas
link
abnorm
high
glycogen
synthas
kinas
level
alzheim
type
diabet
jazag
et
al
provid
similar
exampl
cornaibas
analys
complex
signal
transduct
pathway
inhibit
individu
gene
could
account
whole
process
target
smad
transcript
factor
mediat
transform
growth
cytostat
respons
mani
cell
type
latter
clincial
interest
loss
contribut
tumorigenesi
use
separ
shrna
differ
smad
author
establish
stabl
cell
line
express
one
two
three
hairpin
similar
result
gonzalez
et
al
shrna
express
smad
knockdown
could
maintain
least
passag
like
owe
small
shrna
number
low
express
level
integr
plasmid
hope
phenotyp
analys
variou
cell
line
reveal
differ
contribut
three
smad
paramet
wound
closur
cell
migrat
provid
insight
role
smad
cancer
potenti
cornai
function
gene
studi
substanti
seri
similar
report
cell
cultur
transgen
mice
use
shmirna
cotarget
eg
multipl
sod
gene
cyclin
sphase
kinaseassoci
protein
relat
kinas
braf
craf
particularli
remark
articl
shin
et
al
report
use
tightli
regul
tetracyclineinduc
cornai
system
detail
group
engin
lentivirus
condit
express
two
hairpin
target
heterotrimer
g
protein
analys
report
gene
express
luciferas
fuse
serum
respons
element
allow
delin
specif
role
transmit
receptormedi
serum
respons
element
activ
studi
thu
anoth
illustr
cornai
power
experiment
platform
analysi
potenti
redund
signal
pathway
clinic
standpoint
two
interest
target
therapeut
cornai
hcv
hiv
mention
two
virus
particularli
resist
therapeut
intervent
owe
extrem
natur
genet
divers
potenti
mutat
escap
mani
group
therefor
recent
began
pursu
strategi
cotarget
viral
cellular
gene
encod
host
cofactor
requir
viral
uptak
replic
express
basi
latter
evolutionari
pressur
thu
substanti
less
prone
mutat
grow
number
cellular
protein
alreadi
identifi
play
critic
role
two
virus
individu
silenc
signific
effect
outcom
infect
instanc
zhang
et
al
use
adenovir
deliv
shrna
cellular
la
polypyrimidin
tractbind
protein
human
vesicleassoci
membran
proteinassoci
protein
kd
known
interact
hcv
individu
inhibit
gene
led
reduct
hcv
amplif
replicon
cell
line
suggest
use
futur
cotarget
strategi
includ
viral
genom
promis
cellular
cotarget
viral
co
receptor
inhibit
would
actual
prevent
viral
infect
simpli
block
viral
reproduct
target
viral
gene
howev
fundament
concern
strategi
knock
endogen
gene
could
creat
unaccept
lossoffunct
patholog
cell
therefor
maxim
patient
safeti
potenti
cellular
target
must
chosen
care
evalu
individu
thoroughli
exemplifi
report
korf
et
al
cotarget
two
cellular
hcv
cofactor
hur
hu
antigen
r
bind
hcv
untransl
region
result
stabil
proteasom
modul
hcvintern
ribosom
entri
site
activ
togeth
hcv
genom
untransl
region
transfect
hcv
replicon
cell
line
individu
best
shrna
separ
promot
caus
least
reduct
viral
rna
similar
decreas
hcv
protein
importantli
combin
antihcv
shrna
show
strong
addit
effect
illustr
increas
viral
protein
rna
inhibit
approxim
although
evalu
excit
result
suggest
potenti
particular
cornai
approach
prevent
hcv
escap
mutant
andor
inhibit
multipl
genotyp
provid
share
cellular
factor
hand
therapeut
use
two
cellular
protein
remain
obscur
essenti
function
cell
proteasom
subunit
hur
import
regul
cell
prolifer
anoth
recent
studi
henri
et
al
provid
first
exampl
tripl
shrna
vector
cotarget
hcv
genom
intern
ribosom
entri
site
host
factor
cell
surfac
tetraspanin
bind
hcv
envelop
protein
hcv
replicon
cell
individu
shrna
separ
promot
deliv
lentiviru
effici
reduc
replic
express
specif
target
least
similar
result
respect
individu
target
obtain
cornai
vector
express
two
three
shrna
simultan
import
conclus
lack
competit
among
individu
shrna
absenc
nonspecif
effect
vector
howev
must
note
promot
rel
weak
shrna
level
quantifi
studi
moreov
replicon
cell
reduc
capac
produc
cloud
analysi
potenti
side
effect
cornai
vector
regardless
find
hcv
inhibit
persist
day
stabli
transduc
cell
line
argu
major
advers
effect
provid
anoth
proof
feasibl
establish
longterm
cornai
excit
evalu
fulli
therapeut
potenti
promis
tripl
vector
studi
particular
effect
knockdown
hcv
bind
uptak
recent
uniqu
studi
akashi
et
al
suggest
feasibl
express
long
nt
shrna
human
cell
absenc
ifn
respons
allegedli
result
mismatch
sens
shrna
strand
accordingli
author
use
plasmid
encod
shrna
effici
cotarget
gene
two
distinct
hcv
strain
differ
nine
nucleotid
compar
convent
shrna
longer
hairpin
suppress
isol
also
yield
rapid
knockdown
although
strictli
cornai
approach
studi
notabl
result
impli
gener
multipl
differ
sirna
long
precursor
albeit
truli
character
confirm
strategi
could
theoret
exploit
prevent
resist
target
long
errorpron
region
viral
genom
figur
boden
et
al
among
first
recogn
need
cornai
approach
control
hiv
engin
aav
vector
express
singl
antihiv
tat
shrna
cultur
lymphoma
cell
found
suppress
replic
week
howev
activ
subsequ
lost
highli
resist
hiv
point
mutant
emerg
within
month
prompt
author
suggest
antivir
cornai
futur
therapi
similar
conclus
reach
song
et
al
test
combin
two
differ
sirna
target
viral
cellular
major
coreceptor
macrophag
gene
sirna
cotransfect
monocytederiv
macrophag
observ
strong
synergist
effect
almost
complet
inhibit
hiv
infect
compar
weaker
effect
individu
sirna
similar
boden
et
al
group
thu
favor
vectorbas
cornai
approach
ideal
target
multipl
step
hiv
life
cycl
idea
substanti
lee
et
al
report
accumul
gag
mutant
hivinfect
cell
transduc
antigag
shrna
lentiviru
also
support
da
et
al
note
emerg
hiv
nef
mutant
follow
viru
passag
cell
stabli
express
singl
antinef
shrna
seri
recent
paper
document
power
cosuppress
cellular
hiv
cofactor
receptor
control
hiv
infect
similar
hcv
among
first
anderson
et
al
inhibit
primari
receptor
coreceptor
monocytemacrophagetrop
hiv
tcell
tropic
hiv
coreceptor
bispecif
sirna
construct
engin
target
either
vitro
transcrib
transfect
hivpermiss
cell
includ
peripher
blood
mononuclear
cell
viru
challeng
assay
show
mark
protect
transfect
cell
hiv
particular
combin
construct
studi
import
proofofprincipl
clinic
applic
bispecif
sirna
question
particular
might
caus
ifn
respons
followup
studi
group
engin
lentivir
vector
coexpress
best
shrna
promot
respect
peripher
blood
mononuclear
cell
similar
initi
studi
result
protect
hiv
infect
viral
challeng
assay
howev
remain
test
whether
antireceptor
cornai
approach
suffic
prevent
viral
resist
moreov
clinic
use
hiv
receptor
sole
therapeut
target
remain
valid
one
concern
inhibit
specif
receptor
may
select
viral
variant
use
nontarget
differ
co
receptor
ultim
negat
therapeut
effect
also
might
ideal
target
essenti
cell
surfac
molecul
immunolog
function
contrast
might
dispens
life
asymptomat
individu
homozyg
mutat
likewis
mutat
affect
tcell
develop
matur
least
murin
studi
nevertheless
knockdown
critic
stem
cell
major
target
hiv
therapi
molecul
play
role
cell
home
bone
marrow
sever
group
begun
studi
coinhibit
hiv
gene
therapeut
modal
chang
et
al
use
lentivir
vector
deliv
antihiv
shrna
variou
viruspermiss
cell
type
critic
find
combin
three
vector
direct
highli
conserv
region
viral
pol
int
vpu
gene
outperform
individu
shrna
term
suppress
hiv
stabl
virusproduc
tcell
line
despit
increas
efficaci
possibl
format
prevent
escap
mutant
evalu
shortterm
studi
instead
address
comprehens
recent
studi
ter
brake
colleagu
screen
subtyp
includ
lai
prototyp
highli
conserv
region
author
identifi
potenti
target
batteri
shrna
target
found
transient
effect
promot
studi
three
direct
gag
pol
gene
reveal
strong
individu
protect
hiv
challeng
stabli
transduc
permiss
cell
includ
peripher
blood
mononuclear
cell
intriguingli
three
shrna
combin
one
lentivir
vector
confer
nearresist
viral
infect
import
group
also
studi
emerg
viral
resist
cell
express
one
two
effect
shrna
hope
viral
inhibit
durabl
cornai
cell
line
although
eventu
day
cultur
posit
regardless
shrna
copi
number
although
show
data
author
also
mention
improv
vector
express
four
differ
shrna
separ
distinct
promot
abl
delay
viral
escap
day
strength
articl
first
date
valid
multipl
shrna
approach
suppress
hiv
escap
also
particularli
noteworthi
shrna
care
chosen
concurr
target
subtyp
although
confirm
experiment
import
futur
use
particular
system
investig
genet
stabil
threefold
fourfold
shrna
lentivir
vector
well
potenti
side
effect
uniqu
construct
similarli
intrigu
recent
work
nishitsuji
et
al
show
feasibl
effici
cotarget
two
viral
region
integras
gene
int
attach
site
att
transduc
via
lentivir
vector
cell
individu
shrna
show
potent
inhibitori
effect
hiv
replic
antitat
construct
one
use
boden
et
al
remark
higher
hiv
dose
singl
shrna
longer
abl
control
viru
combin
intand
attspecif
shrna
vector
still
gave
strong
suppress
almost
week
line
previou
work
group
note
emerg
resist
point
mutant
hiv
infect
singl
shrnaexpress
cell
subsequ
gener
shrna
specif
mutant
could
suppress
replic
unexpectedli
combin
wildtyp
mutant
shrna
less
effect
prevent
viral
escap
author
hypothes
intracellular
competit
variou
shrna
vector
target
site
idea
valid
hcv
studi
akashi
et
al
watanab
et
al
group
also
test
long
hairpin
rna
cover
target
region
antiint
shrna
interestingli
construct
abl
cosuppress
wildtyp
mutant
hiv
strain
effect
weak
transient
reason
unknown
nonetheless
articl
togeth
suggest
technic
problem
overcom
safeti
long
hairpin
guarante
combin
multipl
short
long
rna
might
increas
power
cornai
control
viral
resist
collect
studi
review
clearli
valid
promis
cornai
suppress
viral
infect
escap
howev
also
provid
evid
potenti
setback
coexpress
multipl
hairpin
rna
cell
vector
issu
includ
genet
instabl
promot
hairpin
interfer
toxic
side
effect
see
also
conclus
attempt
circumv
problem
group
begun
combin
shmirna
silenc
gene
express
cdna
encod
therapeut
protein
figur
f
next
section
noteworthi
earli
proofofconcept
came
hemmingsmieszczak
et
al
mix
sirna
antisens
oligonucleotid
inhibit
rat
painrel
cation
channel
import
target
pain
research
rational
high
cost
sirna
monotherapi
human
low
effici
antisens
oligonucleotid
hope
cornai
approach
produc
synergist
effect
term
knockdown
cultur
cell
interestingli
agent
target
nonhomolog
region
reason
competit
remain
elus
find
reminisc
studi
nishitsuji
colleagu
describ
unclear
whether
molecular
mechan
relat
even
ident
two
studi
certainli
prompt
caution
attempt
target
singl
site
multipl
inhibitor
jarczak
et
al
among
first
suggest
combin
shrna
hammerhead
ribozym
rz
hcv
treatment
group
target
highli
conserv
viral
untransl
region
variou
shrna
rz
trna
val
promot
individu
transfect
hcv
replicon
cell
line
best
candid
inhibit
hcv
express
approxim
rz
shrna
although
mix
variou
rz
increas
overal
inhibit
margin
notabl
combin
best
rz
shrna
gave
approxim
addit
effect
shrna
irrespect
initi
potenti
howev
combin
shrna
alon
test
studi
import
proofofconcept
particular
confirm
need
target
differ
site
viral
genom
maximum
efficaci
line
watanab
work
moreov
find
use
differ
promot
rz
shrna
express
yield
strongest
addit
effect
substanti
need
avoid
promot
competit
point
relev
antihiv
cornai
approach
mostli
report
john
rossi
group
current
also
prepar
clinic
trial
pilot
studi
group
test
feasibl
combin
two
differ
rnabas
hiv
inhibitor
one
lentivir
vector
although
neither
rnai
trigger
instead
li
et
al
use
ribozym
driven
adenovir
promot
togeth
transactiv
respons
region
decoy
embed
small
nucleolar
rna
ensur
coloc
hiv
tat
nucleoli
infect
cell
result
vector
provid
substanti
greater
surviv
advantag
hivchalleng
primari
stem
cell
compar
individu
ribozym
decoy
shrna
rev
tat
test
parallel
shown
reduc
hiv
substanti
cell
type
period
result
directli
compar
construct
combin
construct
combin
report
followup
studi
rossi
group
present
lentivir
vector
combin
three
inhibitor
earlier
work
figur
novel
construct
suppress
hiv
replic
week
morethanaddit
fashion
compar
singl
doubl
vector
fact
tripl
vector
construct
remain
inhibitori
cell
day
even
challeng
high
hiv
dose
integr
vector
copi
importantli
evid
evolut
escap
mutant
tripl
vector
although
addit
valid
might
need
view
assay
use
group
also
report
minor
unexpect
yet
fulli
understood
find
vector
includ
approxim
fourfold
drop
viral
titer
standard
product
condit
approxim
threefold
lower
transduct
efficaci
cell
versu
singl
shrna
vector
approxim
loss
gfp
green
fluoresc
protein
express
upon
longterm
cultur
tripletransduc
cell
compar
empti
vector
nevertheless
overal
impress
result
uniqu
ingeni
construct
clearli
illustr
power
cornai
hiv
therapi
consequ
slightli
modifi
vector
delet
gfp
marker
gene
soon
test
clinic
trial
use
autolog
hematopoiet
stem
cell
acquir
immunodefici
syndromelymphoma
patient
bone
marrow
transplant
anoth
invent
antihiv
cornai
strategi
recent
report
rossi
group
involv
combin
shrna
human
transdomin
neg
mutant
hiv
rev
protein
figur
rev
attract
antivir
target
mediat
nuclear
export
singli
splice
unsplic
fulllength
genom
rna
hiv
life
cycl
point
mutat
nuclear
export
signal
provid
rev
variant
abil
inhibit
hiv
replic
render
power
therapeut
alreadi
clinic
evalu
unwalla
et
al
creat
lentivir
vector
antirev
shrna
express
hivinduc
rna
polymeras
ii
promot
termin
weak
polyadenyl
signal
permit
readthrough
downstream
code
sequenc
thu
gener
function
shrna
protein
promot
stabli
transduc
hivchalleng
cell
doubl
vector
mediat
inhibit
hiv
protein
high
cell
surviv
rate
although
direct
comparison
singl
vector
provid
evid
viral
escap
fact
hiv
point
mutant
previous
evolv
presenc
antirev
shrna
alon
remain
approxim
inhibit
doubl
vector
togeth
impress
result
illustr
power
particular
cornai
approach
prevent
hiv
resist
ident
tripl
rnabas
construct
describ
last
least
addit
coexpress
transdomin
antivir
protein
one
also
envis
synergist
gene
silencingaddit
therapeut
context
one
remark
exampl
samakoglu
et
al
document
cornaiprotein
approach
treatment
sickl
cell
anemia
lentivir
vector
engin
express
recombin
gene
promoterenhanc
carri
intron
shrna
human
sickl
mrna
cell
healthi
human
sickl
cell
anemia
patient
transduc
vector
differenti
erythroid
cell
impress
cell
show
similar
level
normal
specif
reduc
patient
cell
data
impli
synergist
globin
protein
express
rnaimedi
knockdown
hold
promis
stem
cell
therapi
sickl
cell
anemia
gener
togeth
rossi
group
lab
work
latest
studi
pave
way
develop
cornai
strategi
add
delet
gene
function
concurr
treatment
human
disord
although
still
fledgl
area
rapidli
grow
bodi
evid
alreadi
illustr
farreach
potenti
cornai
technolog
emerg
power
modal
battl
notori
challeng
clinic
target
hcv
hiv
human
virus
initi
studi
also
affirm
great
potenti
treatment
metabol
blood
disord
cancer
concurr
cornai
quickli
exceed
expect
use
studi
basic
process
signal
transform
howev
sever
critic
issu
associ
novel
approach
must
resolv
permit
realiz
promis
human
progress
clinic
trial
key
transit
pave
way
cornai
bench
bedsid
safeti
stabil
efficaci
safeti
concern
base
plethora
earlier
report
unexpect
advers
side
effect
monornai
treatment
includ
offtarget
silenc
ifn
respons
translat
inhibit
although
obviou
risk
may
increas
proport
cornai
approach
anoth
specif
concern
oversatur
endogen
rnai
machineri
might
least
result
competit
reduct
effect
individu
silenc
could
inde
explain
find
describ
yet
worst
case
overwhelm
individu
factor
rnai
pathway
result
global
dysregul
endogen
mirna
process
dramat
possibl
outcom
illustr
recent
studi
persist
highlevel
shrna
express
mous
liver
optim
aav
vector
led
perturb
mirna
biosynthesi
frequent
construct
direct
six
differ
target
result
liver
toxic
cellular
regener
eventu
lead
loss
rnai
effect
sever
week
howev
almost
case
shrnaassoci
toxic
sever
anim
fail
recov
ultim
die
treatment
although
detail
mechan
toxic
still
investig
line
vivo
data
group
consist
report
concentrationdepend
cytotox
effect
shrna
overexpress
cultur
cell
particularli
noteworthi
recent
studi
et
al
compar
toxic
efficaci
shrna
express
two
differ
rna
polymeras
iii
promot
transcript
weaker
surprisingli
group
found
clear
correl
shrna
express
level
cultur
primari
cell
cytotox
although
underli
mechan
unclear
seem
vari
construct
nevertheless
author
conclud
lower
shrna
number
appear
advantag
maintain
transduc
cell
popul
also
line
recent
observ
substanti
increas
rnai
persist
mice
treat
aav
vector
express
shrna
promot
compar
robust
dg
mak
unpublish
result
unfortun
publish
work
yet
defin
limit
number
exogen
hairpin
rna
effect
incorpor
co
rnai
treatment
like
vari
type
cell
organ
knowledg
avail
one
overemphas
need
find
potent
target
site
hairpin
rna
care
optim
cornai
vector
design
work
lowest
concentr
possibl
might
especi
benefici
adapt
latest
condit
promot
system
cornai
purpos
ideal
allow
restrict
gene
silenc
defin
subpopul
cell
therebi
mimiz
global
risk
organ
excit
recent
exampl
includ
promot
specif
activ
hcvor
hivinfect
cell
epigenet
revers
control
use
exogen
drug
small
molecul
use
altern
promot
might
concurr
help
circumv
second
concern
cornai
ie
genet
instabl
multicompon
vector
although
technic
feasibl
accommod
multipl
shmirna
cassett
virtual
present
viral
vector
includ
smallest
aav
hardli
data
point
like
risk
recombin
delet
caus
sequenc
similar
ident
among
individu
element
anecdot
evid
suggest
problem
exist
could
hamper
approach
might
instanc
explain
report
difficulti
implement
six
ident
shrna
singl
plasmid
one
strategi
circumv
problem
would
use
differ
promot
hairpin
includ
convent
well
abovement
novel
system
howev
result
disproport
express
level
base
promot
strength
might
inadvert
obscur
contribut
individu
compon
altern
alreadi
demonstr
perhap
prefer
vector
engin
express
multipl
mirnalik
hairpin
singl
rna
polymeras
ii
promot
could
simultan
maxim
genet
stabil
spatiotempor
control
hand
discrep
find
avail
effici
multimirna
vector
clearli
indic
implement
strategi
requir
improv
understand
cellular
mechan
govern
process
hairpin
concatem
novel
therapi
stringent
test
cornai
strategi
evalu
anim
model
innat
acquir
genet
diseas
viral
infect
importantli
vivo
trial
allow
us
evalu
efficaci
new
vector
directli
also
provid
us
better
clue
physiolog
role
put
viral
encod
rnai
suppressor
thu
far
major
relat
find
obtain
artifici
system
use
either
robust
plasmid
sr
express
oppos
perhap
lowlevel
express
intact
viru
heterolog
readout
eg
use
nonvertebr
cell
mammalian
factor
thu
possibl
physiolog
condit
becom
obviou
effect
viral
srss
overestim
would
agre
perplex
fact
mani
virus
propos
encod
srss
actual
seem
hijack
endogen
rnai
pathway
reli
cellular
viral
mirna
agenda
one
exampl
hcv
fortun
first
replicationcompet
wildtyp
isol
avail
possibl
excit
studi
seemingli
intric
interplay
viru
rnai
machineri
natur
scenario
lesson
learn
certainli
influenc
futur
design
cornai
vector
respect
import
srsspecif
silenc
gener
expect
benefit
studi
help
us
optim
manifold
cornai
paramet
balanc
viral
cellular
target
possibl
associ
toxic
vectorrel
issu
dose
deliveri
final
studi
might
reveal
whether
cornai
overcom
particular
side
effect
convent
antihiv
highli
activ
antiretrovir
therapi
ie
gener
multidrugresist
highli
infecti
viral
strain
certainli
hope
extrem
efficaci
note
thu
far
mean
advers
effect
occur
cornaibas
therapi
conclus
anticip
excit
elucid
whether
cornai
technolog
live
promis
clinic
studi
ultim
prove
win
strategi
battl
evolv
target
optimist
essenti
advantag
race
rnai
might
primari
human
innat
immun
defens
virus
may
still
lag
develop
effici
countermechan
inher
modular
cornai
anoth
particular
benefit
allow
us
combin
rnai
effici
antivir
therapeut
includ
convent
smallmolecul
protein
drug
particularli
excit
candid
emerg
potenti
futur
rnai
partner
aptam
rna
oligonucleotid
abl
bind
ligand
high
specif
affin
fact
recent
work
demonstr
rna
aptam
express
rna
polymeras
iii
promot
ident
shrna
open
possibl
combin
rnai
trigger
multicompon
vector
moreov
aptam
fuse
sirna
permit
target
rnai
deliveri
incorpor
shrna
loop
regulatori
element
last
least
draw
upon
grow
knowledg
endogen
rnai
pathway
improv
viral
vector
design
refin
bioinformat
model
viral
infect
abl
enhanc
efficaci
approach
therefor
first
time
histori
antivir
therapi
balanc
power
could
decis
tip
favor
